Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Solnatide for pulmonary permeability edema in mechanically ventilated COVID-19 ARDS patients
2020-001244-26Phase 2Terminated
- Sponsor
- Medical University of Vienna
- Start
- Mar 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of solnatide in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19), sponsored by Medical University of Vienna. Primary endpoint: Ventilator-free days within 28 days. Started Mar 2020; status: terminated.
02
Drugs
solnatide
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-001244-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001244-26.